<table id="t2" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Clinically Significant Drug Interactions with Diclofenac
</caption>
<col align="left" width="26.000%"></col>
<col align="left" width="74.000%"></col>
<tbody>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Drugs That Interfere with Hemostasis</content>
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<list listtype="unordered" stylecode="Disc">
<item>Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.
</item>
<item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.
</item>
</list>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor patients with concomitant use of diclofenac with anticoagulants (e.g., warfarin), antiplatelet agents
            
    
     <br/>(e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding (
            
    
     <content stylecode="italics">see 
             
     
      <linkhtml href="#s39">PRECAUTIONS</linkhtml>; 
             
     
      <linkhtml href="#s38">Hematological Toxicity</linkhtml>
</content>).

           
   
    </td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Aspirin</content>
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone 
            
    
     <content stylecode="italics">(see</content>
<br/>
<content stylecode="italics">WARNINGS; Gastrointestinal Bleeding, Ulceration, and 
             
     
      <linkhtml href="#s25">Perforation</linkhtml>)
            
    
     </content>.

           
   
    </td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of diclofenac and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding (
            
    
     <content stylecode="italics">see 
             
     
      <linkhtml href="#s39">PRECAUTIONS: Hematological Toxicity</linkhtml>
</content>).
            
    
     <br/>Diclofenac is not a substitute for low dose aspirin for cardiovascular protection.

           
   
    </td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content>
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<list listtype="unordered" stylecode="Disc">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).
</item>
<item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible
</item>
</list>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<list listtype="unordered" stylecode="Disc">
<item>During concomitant use of diclofenac and
</item>
<item>ACE-inhibitors, ARBs, or betablockers, monitor blood pressure to ensure that the desired blood pressure is obtained.
</item>
<item>During concomitant use of diclofenac and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function (
              
      
       <content stylecode="italics">see 
               
       
        <linkhtml href="#s31">WARNINGS; Renal Toxicity and Hyperkalemia</linkhtml>
</content>).

             
     
      </item>
<item>When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.
</item>
</list>
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Toprule Botrule Lrule Rrule" valign="top">Diuretics
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">During concomitant use of diclofenac with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (
            
    
     <content stylecode="italics">see 
             
     
      <linkhtml href="#s31">WARNINGS; Renal Toxicity and Hyperkalemia</linkhtml>
</content>).

           
   
    </td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">Digoxin
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">During concomitant use of diclofenac and digoxin, monitor serum digoxin levels.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">Lithium
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">During concomitant use of diclofenac and lithium, monitor patients for signs of lithium toxicity.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">Methotrexate
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">During concomitant use of diclofenac and methotrexate, monitor patients for methotrexate toxicity.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">Cyclosporine
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of diclofenac and cyclosporine may increase cyclosporine's nephrotoxicity.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">During concomitant use of diclofenac and cyclosporine, monitor patients for signs of worsening renal function.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">NSAIDs and Salicylates
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (
            
    
     <content stylecode="italics">see 
             
     
      <linkhtml href="#s25">WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation</linkhtml>
</content>).

           
   
    </td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The concomitant use of diclofenac with other NSAIDs or salicylates is not recommended.
</td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">Pemetrexed
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant use of diclofenac and pemetrexed may increase the risk of pemetrexedassociated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="justify" stylecode="Botrule Rrule" valign="top">During concomitant use of diclofenac and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.
            
    
     <br/>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.
            
    
     <br/>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.

           
   
    </td>
</tr>
<tr>
<td align="left" colspan="2" stylecode="Botrule Lrule Rrule" valign="top">CYP2C9 Inhibitors or Inducers:
</td>
</tr>
<tr>
<td align="justify" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">A dosage adjustment may be warranted when diclofenac is administered with CYP2C9 inhibitors or inducers (
            
    
     <content stylecode="italics">see 
             
     
      <linkhtml href="#s8">CLINICAL PHARMACOLOGY; Pharmacokinetics</linkhtml>
</content>).

           
   
    </td>
</tr>
</tbody>
</table>